600521 华海药业
已收盘 07-24 15:00:00
资讯
新帖
简况
华海药业(600521.SH)子公司获注射用HB0043新增皮下注射给药途径临床试验许可
智通财经 · 07-24 17:38
华海药业(600521.SH)子公司获注射用HB0043新增皮下注射给药途径临床试验许可
华海药业最新公告:琥珀酸亚铁片获药品注册证书
证券之星 · 07-23 18:06
华海药业最新公告:琥珀酸亚铁片获药品注册证书
每周股票复盘:华海药业(600521)出售金融资产获净利3512万
证券之星 · 07-19
每周股票复盘:华海药业(600521)出售金融资产获净利3512万
华海药业获得发明专利授权:“一种精制左旋多巴的方法”
证券之星 · 07-18
华海药业获得发明专利授权:“一种精制左旋多巴的方法”
华海药业汛桥基地收到FDA“问题清单”,涉及13项生产缺陷
蓝鲸财经 · 07-15
华海药业汛桥基地收到FDA“问题清单”,涉及13项生产缺陷
华海药业获得发明专利授权:“一种阿哌沙班乙酯化物的制备方法”
证券之星 · 07-11
华海药业获得发明专利授权:“一种阿哌沙班乙酯化物的制备方法”
华海药业(600521)披露公司产品进入国家基本药物目录,7月10日股价上涨3.57%
证券之星 · 07-10
华海药业(600521)披露公司产品进入国家基本药物目录,7月10日股价上涨3.57%
7月6日华海药业涨9.02%,兴业医疗保健混合A基金重仓该股
证券之星 · 07-06
7月6日华海药业涨9.02%,兴业医疗保健混合A基金重仓该股
异动快报:华海药业(600521)7月6日10点30分触及涨停板
证券之星 · 07-06
异动快报:华海药业(600521)7月6日10点30分触及涨停板
华海药业最新公告:预计2026年半年度净利润同比增长85%-95%
证券之星 · 07-05
华海药业最新公告:预计2026年半年度净利润同比增长85%-95%
每周股票复盘:华海药业(600521)获重酒石酸间羟胺注射液注册证
证券之星 · 07-05
每周股票复盘:华海药业(600521)获重酒石酸间羟胺注射液注册证
华海药业最新公告:重酒石酸间羟胺注射液获药品注册证书
证券之星 · 07-02
华海药业最新公告:重酒石酸间羟胺注射液获药品注册证书
华海药业(600521)披露可转换公司债券转股结果暨股份变动公告,7月1日股价上涨2.99%
证券之星 · 07-01
华海药业(600521)披露可转换公司债券转股结果暨股份变动公告,7月1日股价上涨2.99%
每周股票复盘:华海药业(600521)冲回负债增利8200万元
证券之星 · 06-28
每周股票复盘:华海药业(600521)冲回负债增利8200万元
华海药业(600521)披露关于授权择机出售公司金融资产的公告,6月26日股价下跌3.98%
证券之星 · 06-26
华海药业(600521)披露关于授权择机出售公司金融资产的公告,6月26日股价下跌3.98%
华海药业(600521.SH)子公司HB0017注射液上市许可申请获得受理
智通财经 · 06-25
华海药业(600521.SH)子公司HB0017注射液上市许可申请获得受理
华海药业(600521)披露仲裁案件进展公告,6月24日股价上涨0.2%
证券之星 · 06-24
华海药业(600521)披露仲裁案件进展公告,6月24日股价上涨0.2%
每周股票复盘:XD华海药(600521)华海药业获三款药品注册证
证券之星 · 06-20
每周股票复盘:XD华海药(600521)华海药业获三款药品注册证
华海药业最新公告:获得甲苯磺酸艾多沙班片等三项药品注册证书
证券之星 · 06-15
华海药业最新公告:获得甲苯磺酸艾多沙班片等三项药品注册证书
华海药业最新公告:获得艾拉莫德片药品注册证书
证券之星 · 06-08
华海药业最新公告:获得艾拉莫德片药品注册证书
加载更多
公司概况
公司名称:
浙江华海药业股份有限公司
所属行业:
医药制造业
上市日期:
2003-03-04
主营业务:
浙江华海药业股份有限公司的主营业务是多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。公司的主要产品是厄贝沙坦氢氯噻嗪片、氯沙坦钾片、厄贝沙坦片、利伐沙班片、安立生坦片、缬沙坦氢氯噻嗪片、缬沙坦氨氯地平片、缬沙坦片、福辛普利钠片、盐酸舍曲林片、奥氮平片、盐酸帕罗西汀片、草酸艾司西酞普兰片、盐酸多奈哌齐片、磷酸奥司他韦胶囊、伏立康唑片、依非韦伦片。
发行价格:
15.55
{"stockData":{"symbol":"600521","market":"SH","secType":"STK","nameCN":"华海药业","latestPrice":16.01,"timestamp":1784876400000,"preClose":16.74,"halted":0,"volume":34592201,"delay":0,"changeRate":-0.0436,"floatShares":1497000000,"shares":1497000000,"eps":0.2493,"marketStatus":"已收盘","change":-0.73,"latestTime":"07-24 15:00:00","open":16.56,"high":16.78,"low":15.99,"amount":565000000,"amplitude":0.0472,"askPrice":16.02,"askSize":395,"bidPrice":16.01,"bidSize":89,"shortable":0,"etf":0,"ttmEps":0.2493,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":5,"adr":0,"adjPreClose":16.74,"symbolType":"stock","openAndCloseTimeList":[[1784856600000,1784863800000],[1784869200000,1784876400000]],"highLimit":18.41,"lowLimit":15.07,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1497252196,"isCdr":false,"pbRate":2.5,"roa":"--","peRate":64.219815,"roe":"4.19%","epsLYR":0.18,"committee":0.110296,"marketValue":23971000000,"turnoverRate":0.0231,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-07-27。","floatMarketCap":23971000000},"requestUrl":"/m/hq/s/600521","defaultTab":"news","newsList":[{"id":"2653083394","title":"华海药业(600521.SH)子公司获注射用HB0043新增皮下注射给药途径临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2653083394","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653083394?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:38","pubTimestamp":1784885932,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华海药业 发布公告,近日,公司下属子公司上海华奥泰生物药业股份有限公司和华博生物医药技术(上海)有限公司收到国家药品监督管理局核准签发的注射用HB0043项目新增皮下注射给药途径的《药物临床试验批准通知书》。据悉,HB0043为全球首款双抗药物,同时靶向白细胞介素-17A和白细胞介素-36受体,具有高结合和阻断活性,开发用于治疗多种难以治疗的自身免疫性疾病,有望突破现有单靶点治疗的局限。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","BK0070","MDTX","IBBJ","BK0201","PSYK","BK0188","BK0239","BK0028","IBBQ","600521","BK0185","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653670746","title":"华海药业最新公告:琥珀酸亚铁片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2653670746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653670746?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:06","pubTimestamp":1784801199,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称,公司近日收到国家药监局核准签发的琥珀酸亚铁片《药品注册证书》,该药品用于缺铁性贫血的预防和治疗,按化学药品3类批准生产可视同通过一致性评价。2025年该药品国内市场销售金额约4.08亿元,公司研发投入约515万元。此次获批将进一步丰富公司产品线,提升市场竞争力。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300037311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600521","BK0185","BK0201","BK0239","BK0028","BK0070","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237159","title":"每周股票复盘:华海药业(600521)出售金融资产获净利3512万","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237159","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652237159?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:31","pubTimestamp":1784395868,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,华海药业报收于16.15元,较上周的16.84元下跌4.1%。本周,华海药业7月16日盘中最高价报17.8元。公司公告汇总浙江华海药业股份有限公司于2026年6月26日召开董事会,授权管理层在12个月内择机出售公司持有的金融资产。截至2026年7月13日,公司通过集中竞价交易方式累计出售共同药业和盟科药业股票,成交金额约10,744.98万元,占公司2025年度净资产的1.14%;累计产生净利润约3,512.44万元,占2025年度净利润的13.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","BK0012","BK0185","BK0028","BK0201","BK0239","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652287244","title":"华海药业获得发明专利授权:“一种精制左旋多巴的方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2652287244","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652287244?lang=zh_cn&edition=full","pubTime":"2026-07-18 03:22","pubTimestamp":1784316141,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示华海药业新获得一项发明专利授权,专利名为“一种精制左旋多巴的方法”,专利申请号为CN202110705840.8,授权日为2026年7月17日。该精制方法适用于规模化生产,所得左旋多巴具有良好的晶体形态。今年以来华海药业新获得专利授权17个,较去年同期增加了70%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071800001641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600521","BK0012","BK0185","BK0028","BK0201","BK0070","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651451582","title":"华海药业汛桥基地收到FDA“问题清单”,涉及13项生产缺陷","url":"https://stock-news.laohu8.com/highlight/detail?id=2651451582","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651451582?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:51","pubTimestamp":1784109072,"startTime":"0","endTime":"0","summary":"图片来源:FDA官网蓝鲸新闻7月15日讯根据美国食品药品监督管理局在2026年7月13日披露的信息,华海药业位于临海的汛桥生产基地收到了一份FDA 483检查观察表,其中列出了13大类生产缺陷,覆盖多个关键质量环节。FDA于2018年9月对华海药业某生产基地发布进口禁令,暂停该基地生产的原料药及相关制剂进入美国市场;EMA也认定该生产基地未能充分遵守GMP要求,禁止其生产的缬沙坦原料药进入欧盟市场。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1784108798667662113","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0028","600521","BK4585","LABU","BK0012","BK0239","BK4588","BK0185","BK0188","BK0201","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650412132","title":"华海药业获得发明专利授权:“一种阿哌沙班乙酯化物的制备方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2650412132","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650412132?lang=zh_cn&edition=full","pubTime":"2026-07-11 03:52","pubTimestamp":1783713151,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示华海药业新获得一项发明专利授权,专利名为“一种阿哌沙班乙酯化物的制备方法”,专利申请号为CN202210008948.6,授权日为2026年7月10日。本发明先在无机碱、碘化物和非亲水性有机溶剂中将式化合物与式化合物进行反应,再与酸反应得到阿哌沙班乙酯化物。今年以来华海药业新获得专利授权15个,较去年同期增加了50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071100002946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0070","600521","BK0185","BK0188","BK0012","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650135436","title":"华海药业(600521)披露公司产品进入国家基本药物目录,7月10日股价上涨3.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650135436","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650135436?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:16","pubTimestamp":1783692984,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,华海药业报收于16.84元,较前一交易日上涨3.57%,最新总市值为252.14亿元。该股当日开盘16.06元,最高17.07元,最低15.9元,成交额达9.12亿元,换手率为3.65%。近日,浙江华海药业股份有限公司发布关于公司产品进入国家基本药物目录的公告。公告显示,公司及下属子公司共有54个产品进入《国家基本药物目录》,其中23个产品为新增纳入,包括厄贝沙坦片、缬沙坦片、盐酸多奈哌齐片等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0012","BK0239","600521","BK0028","BK0070","BK0185","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649827642","title":"7月6日华海药业涨9.02%,兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649827642","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649827642?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:22","pubTimestamp":1783326129,"startTime":"0","endTime":"0","summary":"证券之星消息,7月6日华海药业涨9.02%,收盘报16.8元,换手率6.76%,成交量101.28万手,成交额16.91亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。兴业医疗保健混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600021461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0070","600521","BK0185","BK0188","BK0012","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649610817","title":"异动快报:华海药业(600521)7月6日10点30分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2649610817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649610817?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:40","pubTimestamp":1783305640,"startTime":"0","endTime":"0","summary":"证券之星7月6日盘中消息,10点30分华海药业(600521)触及涨停板。其所属行业化学制药目前上涨。领涨股为首药控股。该股为创新药,化学原料药,医药概念热股,当日创新药概念上涨4.1%,化学原料药概念上涨2.61%,医药概念上涨2.59%。7月3日的资金流向数据方面,主力资金净流入4671.08万元,占总成交额10.0%,游资资金净流出1157.55万元,占总成交额2.48%,散户资金净流出3513.53万元,占总成交额7.52%。近5日资金流向一览见下表:华海药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600007608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0070","BK0028","BK0185","BK0188","BK0012","600521","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649618689","title":"华海药业最新公告:预计2026年半年度净利润同比增长85%-95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649618689","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649618689?lang=zh_cn&edition=full","pubTime":"2026-07-05 15:49","pubTimestamp":1783237793,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称,预计2026年半年度归属于上市公司股东的净利润为7.57亿元-7.99亿元,同比增长85%-95%。业绩变动主要系公司拓展全球销售渠道、加快新产品上量,以及缬沙坦欧洲仲裁胜诉和处置子公司股权收益等影响。注:公司Q2净利润预计3.52亿-3.94亿,Q1净利润4.04亿,据此计算,Q2净利润预计环比变动-12%--2%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500003143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649694362","title":"每周股票复盘:华海药业(600521)获重酒石酸间羟胺注射液注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2649694362","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649694362?lang=zh_cn&edition=full","pubTime":"2026-07-05 01:47","pubTimestamp":1783187231,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,华海药业报收于15.41元,较上周的14.01元上涨9.99%。本周关注点来自公司公告汇总:华海药业获重酒石酸间羟胺注射液《药品注册证书》,视同通过一致性评价。公司持有华奥泰96.02%股权。浙江华海药业股份有限公司近日收到国家药品监督管理局核准签发的重酒石酸间羟胺注射液《药品注册证书》,药品批准文号为国药准字H20265022,剂型为注射剂,规格为1ml:10mg,注册分类为化学药品3类。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600521","BK0012","BK0239","BK0185","BK0188","BK0201","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648066795","title":"华海药业最新公告:重酒石酸间羟胺注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2648066795","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648066795?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:51","pubTimestamp":1782985864,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称,公司近日收到国家药监局核准签发的重酒石酸间羟胺注射液的《药品注册证书》。该药品用于防治低血压,按化学药品3类批准生产可视同通过一致性评价。2025年该药品国内市场销售金额约4.04亿元,公司研发投入约598万元。此次获批进一步丰富了公司产品线,有助于提升市场竞争力。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200030661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0201","BK0239","BK0185","BK0012","BK0028","BK0070","600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648806541","title":"华海药业(600521)披露可转换公司债券转股结果暨股份变动公告,7月1日股价上涨2.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648806541","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648806541?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:25","pubTimestamp":1782915918,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘,华海药业报收于14.83元,较前一交易日上涨2.99%,最新总市值为222.04亿元。近日,华海药业发布《可转换公司债券转股结果暨股份变动公告》。2026年第二季度期间,共1,000元华海转债转股,形成60股股份。截至2026年6月30日,尚未转股的可转债金额为1,842,381,000元,占发行总额的99.9881%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0070","BK0012","600521","BK0201","BK0239","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646131393","title":"每周股票复盘:华海药业(600521)冲回负债增利8200万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2646131393","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646131393?lang=zh_cn&edition=full","pubTime":"2026-06-28 02:24","pubTimestamp":1782584652,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,华海药业报收于14.01元,较上周的14.35元下跌2.37%。本周,华海药业6月24日盘中最高价报15.12元。公司公告汇总:股东周明华解除质押2550万股,当前累计质押占总股本3.01%。公司公告汇总浙江华海药业股份有限公司收到山德士支付的7,045,930.69美元,用于补偿公司因仲裁产生的律师费、仲裁费等支出。公司冲回预计负债4,847万元人民币,预计增加2026年度净利润约8,200万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0239","BK0070","BK0012","600521","BK0201","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646336582","title":"华海药业(600521)披露关于授权择机出售公司金融资产的公告,6月26日股价下跌3.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646336582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646336582?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:28","pubTimestamp":1782484100,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,华海药业报收于14.01元,较前一交易日下跌3.98%,最新总市值为209.77亿元。近日,浙江华海药业股份有限公司召开第九届董事会第十三次临时会议,审议通过《关于授权择机出售公司金融资产的议案》。董事会授权经营管理层在符合规定条件下择机出售公司所持相关金融资产。授权期限内,交易金额或产生的净利润达到披露标准时将及时履行信息披露义务。本次授权有效期为自董事会审议通过之日起12个月内。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600045695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","BK0201","BK0188","BK0028","BK0239","BK0012","BK0070","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646768798","title":"华海药业(600521.SH)子公司HB0017注射液上市许可申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2646768798","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646768798?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:22","pubTimestamp":1782379348,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华海药业(600521.SH)发布公告,近日,公司下属子公司上海华奥泰生物药业股份有限公司(简称“华奥泰”)收到国家药品监督管理局签发的HB0017注射液境内生产药品注册上市许可申请的《受理通知书》。申报适应症:用于治疗适合接受系统治疗或光疗的中度至重度斑块状银屑病成人患者。HB0017注射液是华奥泰自主研发的以白介素-17A(IL-17A)为靶点的单克隆抗体,拟用于治疗中重度斑块状银屑病(境内注册上市申请已受理)、强直性脊柱炎(推进III期临床)及其他自身免疫疾病。截至目前,公司在HB0017注射液项目上的研发投入合计约人民币45,403万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","IPOS","BK0012","BK0188","BK0201","BK0185","BK0070","BK0239","600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645899055","title":"华海药业(600521)披露仲裁案件进展公告,6月24日股价上涨0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645899055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645899055?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:48","pubTimestamp":1782294510,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘,华海药业报收于14.72元,较前一交易日上涨0.2%,最新总市值为220.4亿元。浙江华海药业股份有限公司于2026年6月24日发布《关于公司涉及仲裁案件的进展公告》。公告显示,公司收到山德士支付的7,045,930.69美元,系国际商会仲裁院裁决其承担公司为应对仲裁所支出的律师费、仲裁费等费用。本次仲裁案原由山德士因缬沙坦原料药杂质问题提起,仲裁庭裁定公司无需承担违约责任,并驳回山德士的全部请求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400033163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0012","600521","BK0239","BK0201","BK0070","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644632250","title":"每周股票复盘:XD华海药(600521)华海药业获三款药品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2644632250","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644632250?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:25","pubTimestamp":1781893512,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,XD华海药报收于14.35元,较上周的14.45元下跌0.69%。本周,XD华海药6月15日盘中最高价报14.75元。本周关注点公司公告汇总:华海药业及子公司获甲苯磺酸艾多沙班片等三款药品注册证书。公司公告汇总浙江华海药业股份有限公司及下属子公司浙江华海制药科技有限公司近日收到国家药监局核准签发的甲苯磺酸艾多沙班片、培哚普利氨氯地平片、雷米普利片的《药品注册证书》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0188","BK0185","BK0239","600521","BK0012","BK0070","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643272124","title":"华海药业最新公告:获得甲苯磺酸艾多沙班片等三项药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2643272124","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643272124?lang=zh_cn&edition=full","pubTime":"2026-06-15 18:10","pubTimestamp":1781518259,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称,公司及下属全资子公司制药科技近日收到国家药监局核准签发的甲苯磺酸艾多沙班片、培哚普利氨氯地平片(III)、雷米普利片的《药品注册证书》。上述产品按化学药品4类批准生产可视同通过一致性评价,进一步丰富了公司产品线,有助于提升市场竞争力。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500023889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0028","BK0188","BK0185","600521","BK0070","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641604483","title":"华海药业最新公告:获得艾拉莫德片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2641604483","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641604483?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:58","pubTimestamp":1780912689,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称,公司近日收到国家药监局核准签发的艾拉莫德片《药品注册证书》。该药品用于治疗活动性类风湿关节炎,按化学药品4类批准生产视同通过一致性评价。该产品获批将进一步丰富公司产品线,提升市场竞争力。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800024776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600521","BK0028","BK0012","BK0188","BK0070","BK0201","BK0185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784927385036,"stockEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":0.0876},{"period":"3month","weight":0.0256},{"period":"6month","weight":-0.0588},{"period":"1year","weight":-0.255},{"period":"ytd","weight":-0.05}],"compareEarnings":[{"period":"1week","weight":0.0133},{"period":"1month","weight":-0.0722},{"period":"3month","weight":-0.0651},{"period":"6month","weight":-0.0778},{"period":"1year","weight":0.0578},{"period":"ytd","weight":-0.039}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江华海药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"89340人(较上一季度增加8.11%)","perCapita":"16759股","listingDate":"2003-03-04","address":"浙江省台州市临海市汛桥镇汛大路88号","registeredCapital":"149725万元","survey":" 浙江华海药业股份有限公司的主营业务是多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。公司的主要产品是厄贝沙坦氢氯噻嗪片、氯沙坦钾片、厄贝沙坦片、利伐沙班片、安立生坦片、缬沙坦氢氯噻嗪片、缬沙坦氨氯地平片、缬沙坦片、福辛普利钠片、盐酸舍曲林片、奥氮平片、盐酸帕罗西汀片、草酸艾司西酞普兰片、盐酸多奈哌齐片、磷酸奥司他韦胶囊、伏立康唑片、依非韦伦片。","listedPrice":15.55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华海药业,600521,华海药业股票,华海药业股票老虎,华海药业股票老虎国际,华海药业行情,华海药业股票行情,华海药业股价,华海药业股市,华海药业股票价格,华海药业股票交易,华海药业股票购买,华海药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}